Amer Bio Medica

PINK:ABMC USA Diagnostics & Research
Market Cap
$4.81K
Market Cap Rank
#46506 Global
#14485 in USA
Share Price
$0.00
Change (1 day)
+0.00%
52-Week Range
$0.00 - $0.00
All Time High
$1.19
About

American Bio Medica Corporation engages in manufacture and sale of lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rap… Read more

Amer Bio Medica (ABMC) - Total Assets

Latest total assets as of March 2023: $659.00K USD

Based on the latest financial reports, Amer Bio Medica (ABMC) holds total assets worth $659.00K USD as of March 2023.

Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Amer Bio Medica - Total Assets Trend (1996–2022)

This chart illustrates how Amer Bio Medica’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.

Amer Bio Medica - Asset Composition Analysis

Current Asset Composition (December 2022)

Amer Bio Medica's total assets of $659.00K consist of 60.6% current assets and 39.4% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $0.00 2.7%
Accounts Receivable $284.00K 22.4%
Inventory $379.00K 29.9%
Property, Plant & Equipment $479.00K 37.8%
Intangible Assets $0.00 0.0%
Goodwill $0.00 0.0%

Asset Composition Trend (1996–2022)

This chart illustrates how Amer Bio Medica's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Amer Bio Medica's current assets represent 60.6% of total assets in 2022, a decrease from 95.7% in 1996.
  • Cash Position: Cash and equivalents constituted 2.7% of total assets in 2022, down from 42.9% in 1996.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 1996.
  • Asset Diversification: The largest asset category is property, plant & equipment at 37.8% of total assets.

Amer Bio Medica Competitors by Total Assets

Key competitors of Amer Bio Medica based on total assets are shown below.

Company Country Total Assets
ADCNF
OTCGREY:ADCNF
USA $4.51 Billion
Berry Genomics Co Ltd
SHE:000710
China CN¥2.34 Billion
Malaysian Genomics Resource
KLSE:0155
Malaysia RM20.70 Million
NSN Co. Ltd
KQ:031860
Korea ₩60.96 Billion
JOONGANG DNM Co.Ltd
KQ:051980
Korea ₩121.79 Billion
GeneMatrix Inc
KQ:109820
Korea ₩28.03 Billion
Genoray Co. Ltd
KQ:122310
Korea ₩125.67 Billion
Green Cross Lab Cell Corporation
KQ:144510
Korea ₩565.79 Billion

Amer Bio Medica - Asset Efficiency Metrics

Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.

Asset Turnover Ratio

Measures how efficiently a company uses its assets to generate sales

Historical Range: 0.72 - 2.15

Strong asset utilization - Amer Bio Medica generates 0.72x its asset value in annual revenue.

Return on Assets (ROA)

Measures how efficiently a company uses its assets to generate profits

Historical Range: -111.11% - -8.77%

Negative ROA - Amer Bio Medica is currently not profitable relative to its asset base.

Amer Bio Medica - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.59 0.36 1.05
Quick Ratio 0.50 0.22 0.35
Cash Ratio 0.00 0.00 0.00
Working Capital $-458.00K $ -1.83 Million $ 90.00K

Amer Bio Medica - Advanced Valuation Insights

This section examines the relationship between Amer Bio Medica's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio -
Latest Market Cap to Assets Ratio 0.00
Asset Growth Rate (YoY) -32.6%
Total Assets $1.27 Million
Market Capitalization $3.55K USD

Valuation Analysis

Below Book Valuation: The market values Amer Bio Medica's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Amer Bio Medica's assets decreased by 32.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Amer Bio Medica (1996–2022)

The table below shows the annual total assets of Amer Bio Medica from 1996 to 2022.

Year Total Assets Change
2022-12-31 $1.27 Million -32.61%
2021-12-31 $1.88 Million -2.23%
2020-12-31 $1.93 Million -7.31%
2019-12-31 $2.08 Million -16.04%
2018-12-31 $2.48 Million -14.39%
2017-12-31 $2.89 Million -14.24%
2016-12-31 $3.37 Million -11.22%
2015-12-31 $3.80 Million -6.89%
2014-12-31 $4.08 Million -17.88%
2013-12-31 $4.97 Million +3.91%
2012-12-31 $4.78 Million -15.21%
2011-12-31 $5.64 Million -6.30%
2010-12-31 $6.01 Million -14.56%
2009-12-31 $7.04 Million -22.94%
2008-12-31 $9.14 Million -0.15%
2007-12-31 $9.15 Million +1.47%
2006-12-31 $9.02 Million +13.59%
2005-12-31 $7.94 Million -5.22%
2004-12-31 $8.38 Million +23.56%
2003-12-31 $6.78 Million +20.01%
2002-12-31 $5.65 Million +11.05%
2001-12-31 $5.09 Million +0.95%
2000-12-31 $5.04 Million +13.60%
1999-12-31 $4.43 Million -17.87%
1998-12-31 $5.40 Million +31.49%
1997-12-31 $4.11 Million 0.00%
1996-12-31 $4.11 Million --